Changting Meng

1.7k total citations · 1 hit paper
32 papers, 1.1k citations indexed

About

Changting Meng is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Changting Meng has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Changting Meng's work include Cancer Immunotherapy and Biomarkers (8 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Changting Meng is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Changting Meng collaborates with scholars based in United States, China and Japan. Changting Meng's co-authors include Chunmei Bai, Qiang Tian, Leroy Hood, Thomas D. Brown, J. Cruz, Thomas Mueller, B. Sis, David S. Wishart, Philip F. Halloran and Kim Solez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Changting Meng

26 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Gut Microbiota and Gastrointestinal Cancer

2018 313 citations Changting Meng, Chunmei Bai et al. profile →

Peers

Countries citing papers authored by Changting Meng

Since Specialization

Citations

This map shows the geographic impact of Changting Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changting Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changting Meng more than expected).

Fields of papers citing papers by Changting Meng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changting Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changting Meng. The network helps show where Changting Meng may publish in the future.

Co-authorship network of co-authors of Changting Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Changting Meng. A scholar is included among the top collaborators of Changting Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changting Meng. Changting Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers 2025 ·ESMO Open ·Steven B. Maron, Keisho Chìn, Fadi S. Braiteh, Seiichiro Mitani, (unknown), Yuko Kuboki, Mary F. Mulcahy, Joaquina Baranda, (unknown), Ning Jin, Satoshi Hamauchi, Jason Kaplan, Seema Rao Gorla, Sheng Liu, Marcin Woźniak, (unknown), (unknown), Changting Meng, Soichiro Kondo	0
2	1329MO Enfortumab vedotin plus pembrolizumab (EV + P) as first-line (1L) treatment in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Results from a cohort of the EV-202 trial 2025 ·Annals of Oncology ·Paul Swiecicki, George J. Hanna, (unknown), (unknown), Missak Haigentz, Yoichi Honma, Justine Y. Bruce, Kaoru Tanaka, (unknown), (unknown), Jason Kaplan, Sheng Liu, Seema Rao Gorla, Changting Meng, (unknown)	0
3	3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y 2025 ·Annals of Oncology ·Terence W. Friedlander, Peter H. O’Donnell, (unknown), Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Rana R. McKay, (unknown), Saby George, Jason R. Brown, Mehmet Asım Bilen, Delphine Borchiellini, Marco Iafolla, Abhishek Bavle, M. C. Mihm, Y. Zhu, Changting Meng, Jacob Rosenberg	0
4	LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study 2025 ·Annals of Oncology ·Christof Vulsteke, (unknown), Pongwut Danchaivijitr, (unknown), Alejo Rodríguez‐Vida, Zuo‐Feng Zhang, (unknown), (unknown), Steffen Rausch, (unknown), (unknown), (unknown), (unknown), Peter H. O’Donnell, Martin Mihm, Changting Meng, (unknown), (unknown), Blanca Homet Moreno, (unknown)	1
5	Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study 2025 ·European Journal of Cancer ·Kei Muro, Trevor Feinstein, Joaquina Baranda, (unknown), Noriko Yanagitani, (unknown), Leena Gandhi, Toshihiro Kudo, Naomi Fujioka, Jason Kaplan, Seema Rao Gorla, Shubin Liu, (unknown), (unknown), (unknown), Changting Meng, Tejas Patil	0
6	Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results. 2025 ·Journal of Clinical Oncology ·Nataliya Mar, Daniel P. Petrylak, Christopher Hoimes, Jonathan E. Rosenberg, Thomas W. Flaig, Theodore Stewart Gourdin, Pedro C. Barata, (unknown), Mehmet Asım Bilen, Saby George, Santosh Rao, (unknown), Earle F. Burgess, Brian Lewis, Sandy Srinivas, Seema Rao Gorla, Changting Meng, (unknown), Peter H. O’Donnell	0
7	Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202. 2024 ·Journal of Clinical Oncology ·Kei Muro, Keisho Chìn, Steven B. Maron, Fadi S. Braiteh, Seiichiro Mitani, Hiroki Hara, Yasutoshi Kuboki, Mary F. Mulcahy, Joaquina Baranda, (unknown), Ning Jin, Satoshi Hamauchi, Jason Kaplan, Seema Rao Gorla, Shubin Liu, (unknown), Changting Meng, Shunsuke Kondo	2
8	Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer 2024 ·Journal of Clinical Oncology ·Paul Swiecicki, Emrullah Yilmaz, Ari J. Rosenberg, (unknown), Justine Y. Bruce, Changting Meng, (unknown), Yupei Zhao, (unknown), Jason Kaplan, Seema Rao Gorla, J.L. Geiger	9
9	Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Paul Swiecicki, Emrullah Yilmaz, Ari J. Rosenberg, Takeshi Fujisawa, Justine Y. Bruce, Changting Meng, Matthew A. Wozniak, Ling Wang, Seema Rao Gorla, J.L. Geiger	1
10	Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial. 2024 ·Journal of Clinical Oncology ·Paul Swiecicki, Ari J. Rosenberg, Glenn J. Hanna, Justine Y. Bruce, Takao Fujisawa, Yoshitaka Honma, Kei Muro, Jason Kaplan, Seema Rao Gorla, Shubin Liu, Changting Meng, J.L. Geiger	2
11	The transcriptomic landscape of normal and ineffective erythropoiesis at single-cell resolution 2023 ·Blood Advances ·Raymond T. Doty, Christopher Lausted, Adam D. Munday, Zhantao Yang, Xiaowei Yan, Changting Meng, Qiang Tian, Janis L. Abkowitz	9
12	Single-cell analysis of erythropoiesis in Rpl11 haploinsufficient mice reveals insight into the pathogenesis of Diamond–Blackfan anemia 2021 ·Experimental Hematology ·Raymond T. Doty, Xiaowei Yan, Changting Meng, Christopher Lausted, Qiang Tian, Janis L. Abkowitz	8
13	1331P Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC) 2021 ·Annals of Oncology ·Alona Zer, Julia Dudnik, Sivan Shamai, Maya Gottfried, Aviad Zick, Ayelet Shai, (unknown), (unknown), Fang Yang, (unknown), Changting Meng, Paul Duic, (unknown), Eric Sbar, Jatin P. Shah, Michael Kauffman, Sharon Shacham, Talia Golan	1
14	Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression 2021 ·BMC Pulmonary Medicine ·Yingyi Wang, Na Zhou, Rui Zhu, Xiaoyuan Li, Zhao Sun, Yang Gao, Wei Liu, Changting Meng, (unknown), Chunmei Bai, Taisheng Li, Hongsheng Liu	15
15	Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors 2015 ·Tumor Biology ·Yuejuan Cheng, Zhao Sun, Chunmei Bai, Xiaoyan Yan, Ran Qin, Changting Meng, (unknown)	13
16	Genetic analysis in a patient with nine primary malignant neoplasms: A rare case of Li-Fraumeni syndrome 2015 ·Oncology Reports ·Xiaoyuan Li, (unknown), Qi Pan, (unknown), Dachun Zhao, Changting Meng, Chunmei Bai, Anil Patwardhan, Richard Chen, Hong Ren, Atul J. Butte, Keyue Ding	3
17	Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study 2014 ·Translational Oncology ·Changting Meng, Hongyan Yin, Zhao Sun, (unknown), Shuchang Chen, Chunmei Bai, Lin Zhao	4
18	MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma 2014 ·BMC Cancer ·Zhao Sun, Changting Meng, Shihua Wang, Na Zhou, Mei Guan, Chunmei Bai, Shan Lu, Qin Han, Robert Chunhua Zhao	82
19	Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas 2014 ·BMC Endocrine Disorders ·Xinwei Qiao, Ling Qiu, Yuan‐Jia Chen, Changting Meng, Zhao Sun, Chunmei Bai, Dachun Zhao, Taiping Zhang, Yupei Zhao, (unknown), Yuhong Wang, Jie Chen, (unknown)	38
20	The Transcriptome of the Implant Biopsy Identifies Donor Kidneys at Increased Risk of Delayed Graft Function 2007 ·American Journal of Transplantation ·Thomas Mueller, J. Reeve, Gian S. Jhangri, Michael Mengel, (unknown), (unknown), (unknown), Gerald Todd, Ronald B. Moore, Konrad S. Famulski, J. Cruz, David S. Wishart, Changting Meng, B. Sis, Kim Solez, Bruce Kaplan, Philip F. Halloran	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact